{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:07:29Z","timestamp":1775228849905,"version":"3.50.1"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007765","name":"Shenyang Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007765","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to retrospectively analyze reported Guillain\u2013Barr\u00e9 syndrome (GBS) cases that occurred after COVID-19 vaccination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Case reports of GBS following COVID-19 vaccination that were published before May 14, 2022, were retrieved from PubMed. The cases were retrospectively analyzed for their basic characteristics, vaccine types, the number of vaccination doses before onset, clinical manifestations, laboratory test results, neurophysiological examination results, treatment, and prognosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Retrospective analysis of 60 case reports revealed that post-COVID-19 vaccination GBS occurred mostly after the first dose of the vaccination (54 cases, 90%) and was common for DNA vaccination (38 cases, 63%), common in middle-aged and elderly people (mean age: 54.5 years), and also common in men (36 cases, 60%). The mean time from vaccination to onset was 12.3 days. The classical GBS (31 cases, 52%) was the major clinical classification and the AIDP subtype (37 cases, 71%) was the major neurophysiological subtype, but the positive rate of anti-ganglioside antibodies was low (7 cases, 20%). Bilateral facial nerve palsy (76% vs 18%) and facial palsy with distal paresthesia (38% vs 5%) were more common for DNA vaccination than for RNA vaccination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>After reviewing the literature, we proposed a possible association between the risk of GBS and the first dose of the COVID-19 vaccines, especially DNA vaccines. The higher rate of facial involvement and a lower positive rate of anti-ganglioside antibodies may be a characteristic feature of GBS following COVID-19 vaccination. The causal relationship between GBS and COVID-19 vaccination remains speculative, more research is needed to establish an association between GBS and COVID-19 vaccination. We recommend surveillance for GBS following vaccination, because it is important in determining the true incidence of GBS following COVID-19 vaccination, as well as in the development of a more safer vaccine.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1078197","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T10:16:20Z","timestamp":1676456180000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Guillain-Barre syndrome following COVID-19 vaccines: A review of literature"],"prefix":"10.3389","volume":"14","author":[{"given":"Miao","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ane.13417","article-title":"The potential neurological effect of the COVID-19 vaccines: A review","volume":"144","author":"Lu","year":"2021","journal-title":"Acta Neurol Scand"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13426","article-title":"Neurological complications of COVID-19: Guillain-barre syndrome following pfizer COVID-19 vaccine","volume":"13","author":"Waheed","year":"2021","journal-title":"Cureus."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1922061","article-title":"Guillain-Barre syndrome should be monitored upon mass vaccination against SARS-CoV-2","volume":"17","author":"Leung","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"B4","first-page":"57e63","article-title":"The miller Fisher syndrome. Review of the literature","volume":"12","author":"Berlit","year":"1992","journal-title":"J Clin Neuroophthalmol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05776-0","article-title":"Miller Fisher syndrome following pfizer COVID-19 vaccine","volume":"43","author":"Abi\u010di\u0107","year":"2022","journal-title":"Neurol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/brain\/awt285","article-title":"Diagnosis of Guillain-Barr\u00e9 syndrome and validation of Brighton criteria","volume":"137","author":"Fokke","year":"2014","journal-title":"Brain."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05523-5","article-title":"Guillain-Barr\u00e9 Syndrome following BNT162b2 COVID-19 vaccine","volume":"42","author":"Trimboli","year":"2021","journal-title":"Neurol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05523-5","article-title":"Electromyoneurography and laboratory findings in a case of Guillain-Barr\u00e9 syndrome after second dose of pfizer COVID-19 vaccine","volume":"17","author":"Scendoni","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"B9","doi-asserted-by":"publisher","first-page":"106887","DOI":"10.1080\/21645515.2021.1954826","article-title":"Guillain-Barr\u00e9 Syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association","volume":"208","author":"Introna","year":"2021","journal-title":"Clin Neurol Neurosurg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106887","article-title":"Guillain-Barr\u00e9 Syndrome after COVID-19 vaccination","volume":"14","author":"McKean","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05467-w","article-title":"A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine","volume":"42","author":"Nasuelli","year":"2021","journal-title":"Neurol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.14712\/18059694.2021.31","article-title":"Guillan-Barr\u00e9 syndrome after first vaccination dose against COVID-19: Case report","volume":"64","author":"\u010cen\u0161\u010d\u00e1k","year":"2021","journal-title":"Acta Med (Hradec Kralove)."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-244527","article-title":"Guillain-Barr\u00e9 Syndrome presenting with facial diplegia following COVID-19 vaccination in two patients","volume":"14","author":"Kanabar","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-242956","article-title":"Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1","volume":"14","author":"Patel","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.12691\/ajmcr-9-8-10","article-title":"Guillain-Barr\u00e9 Syndrome in a 67-year-old Male post COVID-19 vaccination (Astra zeneca)","volume":"9","author":"Azam","year":"2021","journal-title":"Med Case Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011881","article-title":"Guillain- Barr\u00e9 syndrome in the placebo and active arms of a COVID-19 vaccine clinical trial : Temporal associations do not imply causality","volume":"1","author":"M\u00e1rquez Loza","year":"2021","journal-title":"Neurology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2021.e01143","article-title":"Guillain-Barr\u00e9 Syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association","volume":"24","author":"Ogbebor","year":"2021","journal-title":"idcases."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint13030040","article-title":"A novel case of bifacial diplegia variant of Guillain-Barr\u00e9 syndrome following janssen COVID-19 vaccination","volume":"13","author":"Prasad","year":"2021","journal-title":"Neurol Int"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.935275","article-title":"Guillain-Barr\u00e9 Syndrome after Ad26.COV2.S vaccination","volume":"23","author":"Thant","year":"2022","journal-title":"Am J Case Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"577691","DOI":"10.1016\/j.jneuroim.2021.577691","article-title":"Sensory Guillain-barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature","volume":"359","author":"Min","year":"2021","journal-title":"J Neuroimmunol."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05849-0","article-title":"Guillain-Barr\u00e9 Syndrome associated with BNT162b2 COVID vaccination: A first case report from south Korea","volume":"43","author":"Kim","year":"2022","journal-title":"Neurol Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2022.37.e5","article-title":"Guillain-Barre syndrome after two COVID-19 vaccinations: Two case reports with follow-up electrodiagnostic study","volume":"37","author":"Kim","year":"2022","journal-title":"J Korean Med Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4103\/ijph.ijph_1716_21","article-title":"Post coronavirus disease-2019 vaccination Guillain-Barr\u00e9 syndrome","volume":"65","author":"Biswas","year":"2021","journal-title":"Indian J Public Health"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/ncn3.12537","article-title":"Guillain-Barr\u00e9 Syndrome following ChAdOx1 nCoV-19 COVID-19 vaccination: A case series","volume":"9","author":"James","year":"2021","journal-title":"Neurol Clin Neurosci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26143","article-title":"Guillain-Barr\u00e9 Syndrome following ChAdOx1-S\/nCoV-19 vaccine","volume":"90","author":"Maramattom","year":"2021","journal-title":"Ann Neurol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2021.04.005","article-title":"Guillain-Barr\u00e9 Syndrome following first injection of ChAdOx1 nCoV-19 vaccine: first report","volume":"177","author":"Theuriet","year":"2021","journal-title":"Rev Neurol (Paris)."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05733-x","article-title":"Guillain-Barr\u00e9 Syndrome following the first dose of pfizer-BioNTech COVID-19 vaccine: Case report and review of reported cases","volume":"43","author":"Bouattour","year":"2022","journal-title":"Neurol Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"102540","DOI":"10.1016\/j.amsu.2021.102540","article-title":"Post-COVID-19 vaccine Guillain-Barr\u00e9 syndrome; first reported case from Qatar","volume":"67","author":"Razok","year":"2021","journal-title":"Ann Med Surg (Lond)."},{"key":"B29","doi-asserted-by":"publisher","first-page":"108818","DOI":"10.1016\/j.clim.2021.108818","article-title":"Guillain-Barr\u00e9 Syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine","volume":"230","author":"Garc\u00eda-Grimshaw","year":"2021","journal-title":"Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-246701","article-title":"Miller-Fisher syndrome and Guillain-barre syndrome overlap syndrome in a patient post Oxford-AstraZeneca SARS-CoV-2 vaccination","volume":"14","author":"Dang","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3201\/eid2712.211634","article-title":"Guillain-Barr\u00e9 Syndrome associated with COVFukushimaID-19 vaccination","volume":"27","author":"Shao","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcab296","article-title":"A case of sensory ataxic Guillain-Barr\u00e9 syndrome with immunoglobulin G anti-GM1 antibodies following the first dose of mRNA COVID-19 vaccine BNT162b2 (Pfizer)","volume":"115","author":"Fukushima","year":"2022","journal-title":"QJM."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2169\/internalmedicine.8851-21","article-title":"Miller Fisher syndrome following vaccination against SARS-CoV-2","volume":"61","author":"Yamakawa","year":"2022","journal-title":"Intern Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1186\/s12883-021-02489-x","article-title":"Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination","volume":"21","author":"Nishiguchi","year":"2021","journal-title":"BMC Neurol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcac102","article-title":"Guillain-Barr\u00e9 Syndrome after BNT162b2 (Pfizer-BioNTec) vaccination","volume":"115","author":"Takahashi","year":"2022","journal-title":"qjm."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.18071\/isz.74.0286","article-title":"A variant of Guillain-barre syndrome after SARS-CoV-2 vaccination: AMSAN","volume":"74","author":"Tutar","year":"2021","journal-title":"Guillain-Barr\u00e9- szindr\u00f3ma SARS-CoV-2-vakcin\u00e1ci\u00f3t k\u00f6vet\u0151en. Ideggyogy Sz."},{"key":"B37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.pediatrneurol.2021.10.003","article-title":"Guillain-Barr\u00e9 Syndrome after COVID-19 vaccination in an adolescent","volume":"126","author":"Malamud","year":"2022","journal-title":"Pediatr Neurol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2021.07.062","article-title":"Guillain-Barr\u00e9 Syndrome presenting as facial diplegia after COVID-19 vaccination: A case report","volume":"61","author":"Rossetti","year":"2021","journal-title":"J Emerg Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-327027","article-title":"Bilateral facial weakness with paraesthesia variant of Guillain-Barr\u00e9 syndrome following vaxzevria COVID-19 vaccine","volume":"93","author":"Bonifacio","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26144","article-title":"Guillain-Barr\u00e9 Syndrome variant occurring after SARS-CoV-2 vaccination","volume":"90","author":"Allen","year":"2021","journal-title":"Ann Neurol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-243629","article-title":"Case of Guillain-Barr\u00e9 syndrome following COVID-19 vaccine","volume":"14","author":"Hasan","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-008-0775-0","article-title":"Bickerstaffs brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases","volume":"255","author":"Ito","year":"2008","journal-title":"J Neurol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2012.11.014","article-title":"Postvaccination miller Fisher syndrome after combined pertussis, diphtheria and tetanus toxoid vaccine","volume":"66","author":"Kr\u00e4mer","year":"2013","journal-title":"J Infect"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu005","article-title":"Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence","volume":"58","author":"Vellozzi","year":"2014","journal-title":"Clin Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.03.013","article-title":"Atypical forms of Guillain-Barr\u00e9 syndrome and H1N1-influenza vaccination","volume":"30","author":"Shaikh","year":"2012","journal-title":"Vaccine 2012. Vaccine"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jns.12482","article-title":"COVID-19 and the peripheral nervous system. A 2-year review from the pandemic to the vaccine era","volume":"27","author":"Taga","year":"2022","journal-title":"J Peripher Nerv Syst"},{"key":"B47","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/003591576505800503","article-title":"The environment and disease: Association or causation","volume":"58","author":"Ab","year":"1965","journal-title":"Proc R Soc Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1017\/cjn.2021.102","article-title":"Guillain Barre syndrome as a complication of COVID-19: A systematic review","volume":"49","author":"Aladawi","year":"2022","journal-title":"Can J Neurol Sci"},{"key":"B49","unstructured":"COVID-19 vaccine safety update: VAXZEVRIA AstraZeneca AB2021"},{"key":"B50","doi-asserted-by":"publisher","first-page":"n1786","DOI":"10.1136\/bmj.n1786","article-title":"Covid-19: Regulators warn that rare Guillain-Barr\u00e9 cases may link to J&J and AstraZeneca vaccines","volume":"374","author":"Dyer","year":"2021","journal-title":"BMJ"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2009.07.008","article-title":"Isolated ptosis as acute ophthalmoplegia without ataxia, positive for anti-GQ1b immunoglobulin G","volume":"41","author":"Jindal","year":"2009","journal-title":"Pediatr Neurol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2021\/e3286","article-title":"Post SARS-CoV-2 vaccination Guillain-barre syndrome in 19 patients","volume":"76","author":"Finsterer","year":"2021","journal-title":"Clinics (Sao Paulo)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa284","article-title":"Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities","volume":"116","author":"Bienvenu","year":"2020","journal-title":"Cardiovasc Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26258","article-title":"Adenovirus COVID-19 vaccines and Guillain-Barr\u00e9 syndrome with facial paralysis","volume":"91","author":"Pegat","year":"2022","journal-title":"Ann Neurol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awf272","article-title":"Peripheral neuropathies and anti-glycolipid antibodies","volume":"125","author":"Willison","year":"2002","journal-title":"Brain."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2016.1193006","article-title":"Guillain-Barr\u00e9 Syndrome: Causes, immunopathogenic mechanisms and treatment","volume":"12","author":"Jasti","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5196","article-title":"Prediction of post-vaccination Guillain-Barr\u00e9 syndrome using data from a passive surveillance system","volume":"30","author":"Luo","year":"2021","journal-title":"pharmacoepidemiol Drug Saf."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13575","article-title":"Guillain-Barre syndrome following COVID-19 vaccines: A scoping review","volume":"145","author":"Lahoz Fernandez","year":"2022","journal-title":"Acta Neurol Scand ."},{"key":"B59","unstructured":"GBS\/CIDP Foundation InternationalFoundation global medical advisory board statement on COVID vaccines for CIDP and MMN"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.3287","article-title":"Rate of recurent Guillain-barre syndrome after mRNA COVID-19 vaccine BNT162b2","volume":"78","author":"Shapiro Ben David","year":"2021","journal-title":"JAMA Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1078197\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T10:16:35Z","timestamp":1676456195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1078197\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2023.1078197"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1078197","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]},"article-number":"1078197"}}